Idebenone

ApprovedCompleted

0 views this week 0 watching💤 Quiet

Interest: 33/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Leber's Hereditary Optic Neuropathy (LHON)

Conditions

Leber's Hereditary Optic Neuropathy (LHON)

Trial Timeline

May 1, 2016 → Mar 29, 2021

NCT ID

NCT02774005

About Idebenone

Idebenone is a approved stage product being developed by Santhera Pharmaceuticals for Leber's Hereditary Optic Neuropathy (LHON). The current trial status is completed. This product is registered under clinical trial identifier NCT02774005. Target conditions include Leber's Hereditary Optic Neuropathy (LHON).

What happened to similar drugs?

0 of 1 similar drugs in Leber's Hereditary Optic Neuropathy (LHON) were approved

Approved (0) Terminated (1) Active (0)

❌Idebenone + PlaceboSanthera PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (6)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03433807	Pre-clinical	Completed	—	—	Duchenne Muscular Dystrophy
NCT02771379	Pre-clinical	Completed	Sep 1, 2016	Apr 16, 2021	Leber's Hereditary Optic Neuropathy (LHON)
NCT02774005	Approved	Completed	May 1, 2016	Mar 29, 2021	Leber's Hereditary Optic Neuropathy (LHON)
NCT00758225	Phase 2	Completed	Sep 1, 2008	Jan 1, 2011	Duchenne Muscular Dystrophy
NCT00697073	Phase 3	Completed	Jul 1, 2008	May 1, 2010	Friedreich's Ataxia
NCT00993967	Phase 3	Completed	Jun 1, 2007	Jun 1, 2012	Freidreich's Ataxia

Competing Products

4 competing products in Leber's Hereditary Optic Neuropathy (LHON)

See all competitors

Product	Company	Stage	Hype Score
Idebenone + Placebo	Santhera Pharmaceuticals	Phase 2	25
Idebenone 150 MG Oral Tablet	Santhera Pharmaceuticals	Pre-clinical	16
Idebenone	Santhera Pharmaceuticals	Pre-clinical	16
Idebenone + Placebo	Santhera Pharmaceuticals	Phase 3	22